MYB antibody (AA 119-135)

Catalog No. ABIN6940143

Product Details anti-MYB Antibody

Target: MYB (V-Myb Myeloblastosis Viral Oncogene Homolog (Avian) (MYB))

Binding Specificity: AA 119-135

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This MYB antibody is un-conjugated

Application: ELISA, Coating (Coat)

Purification: Purified by Protein A/G

Immunogen: A synthetic peptide, corresponding to aa 119-135 (RRKVEQEGYPQESSKAG) of c-myb onco protein, coupled to KLH

Clone: MYB286

Isotype: IgG1 kappa

Application Details

Application Notes:

Positive Control: Jurkat, MOLT-4, COLO or BT-20 cells. Colon or breast carcinomas.

Known Application: ELISA (Use Ab at 2-4 μg/mL for coating) (Order Ab without BSA), Optimal dilution for a specific application should be determined.

Restrictions: For Research Use only

Handling

Concentration: 200 μg/mL

Buffer: 10 mM PBS with 0.05 % BSA & 0.05 % azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-80 °C

Storage Comment: Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Expiry Date: 24 months

Target Details for MYB

Target: MYB (V-Myb Myeloblastosis Viral Oncogene Homolog (Avian) (MYB))

Alternative Name: MYB (MYB Products)

Synonyms: Cmyb antibody, c-myb antibody, c-myb_CDS antibody, efg antibody, AI550390 antibody, M16449 antibody, cmyb antibody, xmyb antibody, MYB proto-oncogene, transcription factor antibody, myeloblastosis oncogene antibody, MYB proto-oncogene, transcription factor S homeolog antibody, v-myb avian myeloblastosis viral oncogene homolog antibody, MYB antibody, Myb antibody, myb.S antibody, myb antibody

Background: The highly leukemogenic avian retrovirus E26 contains two oncogenes, v-Myb and v-Ets, which are expressed together as a fusion protein. The cellular homolog of v-Myb, designated c-Myb, encodes a transcription factor. Deletion or disruption of a negative regulatory domain mapping within the carboxy-terminal domain of c-Myb results in enhanced transactivating capacity and in parallel, leads to activation of its ability to transform hemopoietic cells. c-Myb is expressed preferentially, but not exclusively, in immature hemopoietic cells and its expression decreases as cells differentiate.

Molecular Weight: ~75kDa

Gene ID: 4602

UniProt: P01104

Pathways: Chromatin Binding, Positive Regulation of Immune Effector Process